Categories: EHRHealthcareNews

Akoya to Participate at Four Upcoming Investor Conferences

MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming investor conferences.

  • H.C. Wainwright 24th Annual Global Investment Conference (New York, NY)
    Presentation on Monday, September 12th at 11.30 AM ET
  • Morgan Stanley 20th Annual Global Healthcare Conference (New York, NY)
    Fireside chat on Wednesday, September 14th at 8:35 AM ET
  • Capital One Spatial Biology & Proteomics Summit (Virtual)
    Spatial Biology & Single Cell panel discussion on Wednesday, September 28th at 10:15 AM ET
    Executive panel discussion on Wednesday, September 28th at 1:00 PM ET
  • Bank of America Healthcare Innovation Forum (Virtual)
    Spatial Biology & Single Cell panel discussion on Thursday, September 29th at 11 AM ET

A live and archived webcast of the Morgan Stanley Global Healthcare Conference will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com 

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

1 hour ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

1 hour ago